普鲁卡因与顺铂并用放射增敏效应的临床观察

RADIO--SENSITIZATION EFFECT OF CISPLATIN IN COMBINATION WITH PROCAINE

为探讨普鲁卡因是否可增强顺铂放射增敏作用,本文对6O例晚期转移或复发癌症体表肿瘤灶进行试验观测。试验组的CR(53.7％)远高于对照组(29.2％);在肿瘤灶直径>3cm者,CR试验与对照组分别为48.3％、16.7％;肿瘤缩小一半所需射线剂量(PRD),试验与对照组分别为15Gy、27.4Gy;放射增敏比(SER)为1.83。

A controlled pilot study to explore the impact of procaine to cisplatin-radiotherapy was undertaken among 60 unresectable patients with superficially located metastatic or recurrent cancer masses. It was disclosed that CR in the trial group(53.7%) was much higher compared to that in the control(29.2%). Such differences between the two groups of lesions, i. e. 48.3% vs 16.7%, were even more marked for those larger than 3cm in diameters. The radiation dose to achieve 50% reduction in tumour size (RRD) for the trial group was figured out to be 15. Gy, whereas that for the control group 27.4Gy, giving a SER of 1.83.